PUBLICATION

Discovery of novel butyrylcholinesterase inhibitors for treating Alzheimer's disease

Authors
Sang, Z., Huang, S., Tan, W., Ban, Y., Wang, K., Fan, Y., Chen, H., Zhang, Q., Liang, C., Mi, J., Gao, Y., Zhang, Y., Liu, W., Wang, J., Dong, W., Tan, Z., Tang, L., Luo, H.
ID
ZDB-PUB-250610-3
Date
2025
Source
Acta pharmaceutica Sinica. B   15: 213421552134-2155 (Journal)
Registered Authors
Dong, Wu
Keywords
Alzheimer's disease, Mechanism of action, Pharmacodynamic studies, Pharmacokinetic studies, Selective BuChE inhibitor
MeSH Terms
none
PubMed
40486835 Full text @ Acta Pharm Sin B
Abstract
Alzheimer's disease (AD) is a common neurodegenerative disorder among the elderly, and BuChE has emerged as a potential therapeutic target. In this study, we reported the development of compound 8e, a selective reversible BuChE inhibitor (eqBuChE IC50 = 0.049 μmol/L, huBuChE IC50 = 0.066 μmol/L), identified through extensive virtual screening and lead optimization. Compound 8e demonstrated favorable blood-brain barrier permeability, good drug-likeness property and pronounced neuroprotective efficacy. Additionally, 8e exhibited significant therapeutic effects in zebrafish AD models and scopolamine-induced cognitive impairments in mice. Further, 8e significantly improved cognitive function in APP/PS1 transgenic mice. Proteomics analysis demonstrated that 8e markedly elevated the expression levels of very low-density lipoprotein receptor (VLDLR), offering valuable insights into its potential modulation of the Reelin-mediated signaling pathway. Thus, compound 8e emerges as a novel and potent BuChE inhibitor for the treatment of AD, with significant implications for further exploration into its mechanisms of action and therapeutic applications.
Genes / Markers
Figures
Show all Figures
Expression
Phenotype
Mutations / Transgenics
Human Disease / Model
Sequence Targeting Reagents
Fish
Antibodies
Orthology
Engineered Foreign Genes
Mapping